Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24068389 | 1.00 | CA14 (0.38) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765710 | 0.99 | CA14 (0.38) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765717 | 0.99 | CA14 (0.38) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765708 | 0.99 | CA14 (0.38) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765703 | 0.99 | CA14 (0.39) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765713 | 0.98 | CA14 (0.38) | CA14L3MBTL1HDAC1HDAC2HDAC6 | |
| SCHEMBL23765711 | 0.95 | CA14 (0.37) | CA14L3MBTL1 | |
| SCHEMBL23765702 | 0.94 | CA14 (0.36) | CA14 | |
| SCHEMBL23765716 | 0.90 | CA14 (0.36) | CA14 | |
| SCHEMBL25755913 | 0.90 | CA14 (0.33) | CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3865152-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | Eubulus Biotherapeutics Inc. (CN) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369853-A1 | TARGETED PROTEASE DEGRADATION PLATFORM | PSMB1, MDM2, XIAP | CA14 1481/4885L3MBTL1 278/4885HDAC1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.